Myriad Genetics Partners with Actress Jackie Tohn to Promote Hereditary Cancer Testing
Event summary
- Myriad Genetics partners with actress Jackie Tohn to raise awareness about hereditary cancer testing using the MyRisk® Hereditary Cancer Test.
- Tohn discovered a BRCA1 gene variant after her father was diagnosed with cancer, leading her to undergo a prophylactic double mastectomy and future oophorectomy.
- The MyRisk test evaluates 63 genes to assess hereditary risk across 11 cancer types, with results available within 14 days.
- Myriad has tested over 3 million patients and was the first laboratory to identify and sequence the BRCA genes.
The big picture
Myriad Genetics' partnership with Jackie Tohn underscores the growing importance of personalized medicine and early detection in cancer prevention. The collaboration aims to educate the public about hereditary cancer risks, particularly among high-risk populations like those of Ashkenazi Jewish ancestry. This initiative aligns with broader industry trends towards preventive healthcare and the use of genetic information to guide clinical decisions.
What we're watching
- Market Expansion
- How Myriad Genetics will leverage celebrity partnerships to expand market reach and awareness of hereditary cancer testing.
- Regulatory Compliance
- Whether Myriad can sustain its leadership position amid evolving regulatory landscapes for genetic testing.
- Technological Advancement
- The pace at which Myriad integrates new genetic markers and technologies into its testing portfolio.
Related topics